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HISTORICAL NOTE
Wilson’s disease: the 60th anniversary of 
Walshe’s article on treatment with penicillamine
Doença de Wilson: o 60° aniversário do artigo de Walshe no tratamento com penicilamina
Hélio A. G. Teive1, Egberto Reis Barbosa2, Andrew J. Lees3
Wilson’s disease (WD) is a rare autosomal recessive met-
abolic disease resulting from mutations in the ATP7B gene, 
which has been mapped to chromosome 13q141,2. The ATP7B 
gene encodes a copper-transporting adenosine triphospha-
tase (ATPase) protein, which is expressed most abundantly 
in the liver and is responsible for biliary copper excretion. 
Because of defects in this gene, copper accumulates in sev-
eral organs, especially the liver, brain (basal ganglia) and 
corneas1,2. Clinically, patients present with predominantly 
hepatic, psychiatric and neurological symptoms, particularly 
dystonia, tremor and parkinsonism. The Kayser-Fleischer ring 
is an important physical sign, and the most important labo-
ratory tests are serum ceruloplasmin and urine copper lev-
els1,2. The worldwide prevalence of WD is 1:30,000 and more 
than 400 distinct disease-causing mutations in the ATP7B 
gene associated with WD have been identified1,2. Treatment 
options for WD patients include copper chelating agents 
such as penicillamine, trientine, ammonium tetrathiomolyb-
date and zinc salts1,3. First used in patients with WD 60 years 
ago, penicillamine is considered the most effective treatment 
for the condition1,3. This review describes historical aspects 
of WD and emphasizes the important contribution made by 
Professor Walshe to the treatment of this disease with his pio-
neering use of penicillamine.
WILSON’S DISEASE – HISTORICAL MILESTONES
Samuel Alexander Kinnier Wilson (1878-1937) published 
his masterpiece “Progressive lenticular degeneration: a familial 
nervous disease associated with cirrhosis of the liver” in 19121,3. 
He described twelve patients: four cases he had seen himself, 
two additional cases from the records of the National Hospital, 
Queen Square, London, UK, and six cases previously published in 
the literature1. From 1913 to 1952, several researchers published 
important contributions to the understanding of WD, includ-
ing: Rumpel (described excess copper in the liver), Gerlach and 
Rohrscheiner (reported excess copper in corneal rings), Kayser, 
Fleischer (Kayser-Fleischer corneal ring), Hall (introduced the 
term hepatolenticular degeneration), Cumings (suggested treat-
ment with British antilewisite), Bearn and Kunkel, and Schieberg 
and Gitlin (reported deficiency of ceruloplasmin in the serum)1,3. 
Three years later, Walshe proposed the use of penicillamine for 
WD treatment, and his seminal paper was published in 19561,4,5. 
Five years after that, Schouwink described the use of zinc salts in 
the treatment of WD1,3, and in 1969 and 1984, Walshe reported 
the use of trientine and tetrathiomolybdate, respectively, for this 
condition1,3. In 1982, Starzl et al. published the first report of liver 
transplantation for WD1,3, and in 1993, three different groups 
identified the gene responsible for WD on chromosome 13q141,3.
1Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Neurologia, Unidade de Distúrbios dos Movimentos, Curitiba PR, Brasil;
2Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Neurologia, São Paulo SP, Brasil; 
3UCL Institute of Neurology, Reta Lila Weston Institute for Neurological Studies, Department of Molecular Neuroscience, London, UK.
Correspondence: Hélio A. G. Teive; Rua General Carneiro, 1103/102; 80060-150 Curitiba PR, Brasil; E-mail: hagteive@mps.com.br
Conflict of interest: There is no conflict of interest to declare.
Received 15 May 2016; Received in final form 17 July 2016; Accepted 28 September 2016.
ABSTRACT
This historical review describes Professor Walshe’s seminal contribution to the treatment of Wilson’s disease on the 60th anniversary of his 
pioneering article on penicillamine, the first effective treatment for the condition.
Keywords: hepatolenticular degeneration; therapeutics; penicillamine.
RESUMO
Esta revisão histórica enfatiza a contribuição seminal do Professor Walshe no tratamento da doença de Wilson (DW), com o seu trabalho 
pioneiro sobre o uso de penicilamina, o primeiro tratamento efetivo do mundo, publicado 60 anos atrás.
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JOHN M. WALSHE AND PENICILLAMINE
Walshe (Figure 1) worked with penicillamine (dimethylcys-
teine), a product of the hydrolysis of penicillin, in the early 1950s 
in Prof. Charles Dent’s laboratory at University College Hospital, 
London, UK1,3,4. He subsequently moved to the liver unit in 
the Thorndike Memorial Laboratory at Boston City Hospital, 
Boston, USA, where he worked under the supervision of Prof. 
Charles Davidson1,3,4. In the same hospital, Prof. Denny-Brown 
was working on WD and treating patients with British antilew-
isite, a drug with important side effects1,4.  Based on his previous 
studies, Walshe suggested to Prof. Davidson that penicillamine 
could be used as a copper-chelating drug4. Following this sug-
gestion, penicillamine was used in one patient with WD, and an 
increase in his urinary copper excretion was observed. However, 
because of various problems, additional tests proved inconclu-
sive1,4. Walshe then returned to the UK and restarted his stud-
ies with penicillamine in WD patients. The first WD patient to 
use penicillamine regularly was Ms S.F., who started treatment 
in 1955, and after one year of follow-up, clinical examination 
showed that penicillamine had been effective1,4. In 1956, Walshe 
published a paper in the American Journal of Medicine under 
the title “Penicillamine, a new oral therapy for Wilson’s dis-
ease”5 (Figure 2). Penicillamine was the first effective treatment 
for patients with WD. However, initial reactions from other 
researchers studying WD were less than enthusiastic, and both 
Denny-Brown in the USA and Cumings in London were very 
critical of Walshe’s discovery4. In 1960, Walshe published another 
paper on the treatment of WD with penicillamine in The Lancet6. 
Ten years after penicillamine was first used to treat WD, its tox-
icity became evident and several side effects were observed. 
These were related to immunologically-mediated reactions, 
including skin lesions (elastosis perforans serpiginosa, epider-
molysis bullosa), systemic lupus erythematosus, nephrotic 
syndrome, Goodpasture syndrome, Ehlers-Danlos syndrome, 
myasthenia gravis, polymyositis, thrombocytopenia and agran-
ulocytosis4,7.  In some patients using penicillamine, a worsen-
ing of the neurological clinical picture (dystonia, parkinsonism) 
was observed4,7. Walshe and Yealland found these unexplained 
side effects in 11 of 137 patients with predominantly neurologi-
cal signs. Various hypotheses have been put forward to explain 
this paradoxical worsening of neurological symptoms, including 
a sudden release of ionic copper, the redox potential of copper, 
a low level of urate in the plasma following treatment with pen-
icillamine and genetic mechanisms (unfavorable mutations in 
the ATP7B gene)4,7. The neurotoxicity and reversible side effects 
of penicillamine motivated various researchers, including Prof. 
Walshe, to look for new drugs to treat WD3,4, and their efforts 
led to trientine, thiomolybdate and zinc therapy being used to 
treat this condition3,4,7. Although penicillamine still remains the 
drug of choice for the treatment of WD, in recent years it has 
become the subject of some controversy because of its well-
known side effects, particularly worsening of the neurological 
symptoms4,7. In 1999, the journal Movement Disorders published 
three very interesting papers about this controversial issue by 
(Courtesy of Professor Walshe)
Figure 1. J. M. Walshe (1920- ).
(Reproduced from reference 5)
Figure 2. Walshe´s first paper about Penicillamine for 
treatment of Wilson´s disease (1956) in the American Journal 
of Medicine.
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Prof. Walshe (“Penicillamine: the treatment of first choice for 
patients with WD”), Prof. Brewer (“Penicillamine should not be 
used as initial therapy in WD”) and Prof. LeWitt (“Penicillamine 
as a controversial treatment for WD”), but no consensus about 
its use was reached, and penicillamine continues to be a treat-
ment option for WD patients8-10.
CONCLUSION
Professor John Walshe pioneered the treatment of 
WD and discovered various drugs that can be used to 
treat the condition, including penicillamine, trientine and 
thiomolybdate. His seminal paper published 60 years ago 
described the first study in which penicillamine was used 
as oral therapy for WD. Penicillamine remains an effective 
drug for treating patients with WD. However, neurologists 
should be aware of the advantages and disadvantages asso-
ciated with its use3,4,7-10.
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